Evaluation of three herbal compounds used for the management of lower urinary tract disease in healthy cats: a pilot study.

Objectives: Lower urinary tract disease (LUTD) occurs commonly in cats, and idiopathic cystitis (FIC) and urolithiasis account for >80% of cases in cats <10 years of age. Although several strategies have been recommended, a common recommendation is to induce dilute urine resulting in more frequent urination and to dilute calculogenic constituents. In addition to conventional therapy using modified diets, traditional Chinese and Western herbs have been recommended, although only one - choreito - has published data available.

Urolithiasis.

Uroliths occur commonly in the bladder and/or urethra of dogs and cats and can be life-threatening if urethral obstruction occurs. The majority of uroliths are composed of struvite or calcium oxalate; however, other minerals such as urate and cystine occur. Uroliths may be composed of more than one mineral.

Congenital diseases of the lower urinary tract.

Congenital lower urinary tract diseases occur with variable frequency and may result in clinical signs of urinary incontinence, urinary obstruction, or urination through abnormal openings. This article discusses diagnosis of congenital diseases of the urinary bladder and urethra and describes treatment of these disorders.

Urinalysis.

Performing a urinalysis should be part of a minimum database in addition to physical examination, historical information gathering, complete blood cell counts, and serum/plasma biochemical analysis. Urinalysis provides information on function of various organs and information on renal function. It is necessary to interpret blood urea nitrogen and serum/plasma creatinine concentrations and is useful in assessing urine concentrating and diluting ability, glomerular barrier function, tubular function, proteinuria, discolored urine, urolithiasis, and neoplasia.

Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo.

The enzyme COX-2 is induced at high levels in tumors but not in surrounding normal tissues, which makes it an attractive target for molecular imaging of cancer. We evaluated the ability of novel optical imaging agent, fluorocoxib A to detect urinary bladder canine transitional cell carcinomas (K9TCC). Here, we show that fluorocoxib A uptake overlapped with COX-2 expression in primary K9TCC cells in vitro.

Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model.

We evaluated preclinical single-dose safety, pharmacokinetic properties, and specific uptake of the new optical imaging agent fluorocoxib A in dogs. Fluorocoxib A, N-[(5-carboxy-X-rhodaminyl)but-4-yl]-2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetamide, selectively binds and inhibits the cyclooxygenase-2 (COX-2) enzyme, which is overexpressed in many cancers. Safety pilot studies were performed in research dogs following intravenous (i.